New presbyopia-correcting eye drops, including VIZZ and Qlosi, offer alternatives to Vuity, with more options under FDA ...

NCX 470 0.1% met the primary endpoint of non-inferiority in IOP reduction compared to latanoprost 0.005% in the Denali trial.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

VivaVision Biotech welcomes renowned ophthalmologist Quan Dong Nguyen to its scientific advisory board with hopes of boosting ...